JAZZ News and Press, Jazz Pharmaceuticals plc From 02/02/22

Jazz Pharmaceuticals (JAZZ -0.5%) completed the submission of a supplemental biologics license application to the U.S. Food and Drug Administration seeking approval for a Monday/Wednesday/Friday intramuscular dosing schedule for Rylaze for use as a component of a multi-agent chemotherape...

Jazz Pharmaceuticals Completes U.S. FDA Supplemental Biologics License Application for Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Monday/Wednesday/Friday Dosing Schedule Phase 2/3 trial data, the basis for submission, demonstrates Rylaze maintains a cl...

The cannabis industry performed horribly in 2021. The Horizons Marijuana Life Sciences ETF , an industry benchmark, has dropped by a little more than 50% over the past 12 months, and many of the top players in the sector didn't do much better. Still, the pot market in North Amer...

The past two years have been hectic, to say the least, largely due to the COVID-19 pandemic. While we've made some progress on that front, the outbreak is far from over. We are currently experiencing a surge in cases due to the omicron variant of the virus. How will things evolve in 2022? I...

Despite having a billion-dollar drug in its portfolio, the potential for backdoor entry into the marijuana market , and being consistently profitable for years, Jazz Pharmaceuticals (NASDAQ: JAZZ) was battered about the head by the stock market last year with its stock falling 2...

Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader Announces $5 billion revenue target for 2025 Confirms 2021 revenue expected to be within previously announced gu...

Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia Treatment with Xywav resulted in clinically meaningful improvement in idiopathic hypersomnia symptoms, including...

Jazz Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire DUBLIN , Jan. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced Bruce Cozadd , chairman and chief executive officer, will present vi...

U.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults ODE for IH for adults follows June 2021 grant of ODE for treatment of cataplexy or excessive daytime sleepiness i...

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder U.S. FDA granted JZP150 Fast Track designation in PTSD, underscoring the unmet needs of patients If approv...